Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.New hope for children with bone cancer has come from a trial showing that patients who have a short course of two anti-cancer drugs fare just as well as those who have a longer course of 10 drugs.
Osteosarcoma is a rare disease mainly affecting young people aged 10 to 20. Standard treatment involves a long course of chemotherapy in which 10 drugs are given over 44 weeks. The side effects of these toxic drugs are sometimes so unpleasant that treatment has to be stopped, raising the risk of a recurrence.
Now researchers in London and New York report in The Lancet that a combination of two drugs is just as effective in eliminating the cancer and is better tolerated by patients. However, the cure rate for osteosarcoma is still "unacceptably low", researchers say, with only two thirds of the patients still alive after five years.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments